> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 3 Observations in MSN Life Sciences Inspection
- URL: https://www.fdaweb.com/3-observations-in-msn-life-sciences-inspection/
- Published: 2026-08-11T12:00:00.000Z
- Updated: 2026-09-14T13:44:54.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161608

FDA has released the Form FDA-483 issued following a 9/9-9/13/2024 inspection at the MSN Life Sciences Private Limited Unit II active pharmaceutical ingredient (API) manufacturing facility in Chandampet, Telangana, India. The three inspection observations were:

- failure to thoroughly investigate critical deviations and/or the failure(s) of a batch to meet specifications;
- failure of the firm’s quality unit to review all critical deviations or non-conformances and related investigations for all API products; and
- failure of the quality unit to perform one of its core responsibilities to ensure that critical deviations are investigated and resolved.